BDBM296465 US10112942, Example 199::US10137124, Example 199::US10172851, Example 199::US10555944, Example 199::US10953005, Example 199

SMILES COc1ccc(CN2CCN(CC2)c2ccc(cn2)-c2cc(OCC3(CO)COC3)cn3ncc(C#N)c23)cn1

InChI Key InChIKey=ZMTHMRJXIRHQNZ-UHFFFAOYSA-N

Data  10 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 296465   

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM296465(US10112942, Example 199 | US10137124, Example 199 ...)
Affinity DataIC50: 50.3nMpH: 7.4Assay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
US Patent

LigandPNGBDBM296465(US10112942, Example 199 | US10137124, Example 199 ...)
Affinity DataIC50: 450nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM296465(US10112942, Example 199 | US10137124, Example 199 ...)
Affinity DataIC50: 50.3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

LigandPNGBDBM296465(US10112942, Example 199 | US10137124, Example 199 ...)
Affinity DataIC50: 450nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

LigandPNGBDBM296465(US10112942, Example 199 | US10137124, Example 199 ...)
Affinity DataIC50: 50.3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
US Patent

LigandPNGBDBM296465(US10112942, Example 199 | US10137124, Example 199 ...)
Affinity DataIC50: 450nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
US Patent

LigandPNGBDBM296465(US10112942, Example 199 | US10137124, Example 199 ...)
Affinity DataIC50: 50.3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
US Patent

LigandPNGBDBM296465(US10112942, Example 199 | US10137124, Example 199 ...)
Affinity DataIC50: 450nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM296465(US10112942, Example 199 | US10137124, Example 199 ...)
Affinity DataIC50: 50.3nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

LigandPNGBDBM296465(US10112942, Example 199 | US10137124, Example 199 ...)
Affinity DataIC50: 450nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent